Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A. Boorjian, Colin P. Dinney, Leonard G. Gomella et al.|The Lancet Oncology|2020Cited by 459
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Gary D. Steinberg, Paras Shah et al.|Nature Medicine|2024Cited by 64